• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.

作者信息

le Roux Carel W, Steen Oren, Lucas Kathryn J, Ekinci Elif I, Startseva Elena, Unseld Anna, Hussain Samina Ajaz, Hennige Anita M

机构信息

St. Vincent's University Hospital and University College Dublin, Dublin, Ireland.

Private practice, Toronto, Ontario, Canada.

出版信息

Diabetes Obes Metab. 2025 Feb;27(2):993-996. doi: 10.1111/dom.16052. Epub 2024 Nov 25.

DOI:10.1111/dom.16052
PMID:39582349
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11701180/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ea/11701180/efcd0fa49fa8/DOM-27-993-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ea/11701180/efcd0fa49fa8/DOM-27-993-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10ea/11701180/efcd0fa49fa8/DOM-27-993-g001.jpg

相似文献

1
Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.司美格鲁肽，一种胰高血糖素受体/胰高血糖素样肽-1受体双重激动剂，可改善肥胖成人的血压：一项随机、安慰剂对照、剂量探索性2期试验的事后分析。
Diabetes Obes Metab. 2025 Feb;27(2):993-996. doi: 10.1111/dom.16052. Epub 2024 Nov 25.
2
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.胰高血糖素和 GLP-1 受体双重激动剂索马鲁肽治疗肥胖症的随机、双盲、安慰剂对照、剂量探索 2 期临床试验。
Lancet Diabetes Endocrinol. 2024 Mar;12(3):162-173. doi: 10.1016/S2213-8587(23)00356-X. Epub 2024 Feb 5.
3
Dose-response effects on HbA and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.与安慰剂和开放标签司美格鲁肽相比，双重胰高血糖素/GLP-1受体激动剂司伏鲁肽对2型糖尿病患者糖化血红蛋白（HbA）和体重减轻的剂量反应效应：一项随机临床试验
Diabetologia. 2024 Mar;67(3):470-482. doi: 10.1007/s00125-023-06053-9. Epub 2023 Dec 14.
4
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.Survodutide，一种胰高血糖素/胰高血糖素样肽-1 受体双重激动剂，在肝硬化中的疗效、耐受性和药代动力学。
J Hepatol. 2024 Nov;81(5):837-846. doi: 10.1016/j.jhep.2024.06.003. Epub 2024 Jun 8.
5
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.MASH 和纤维化中苏沃杜肽的 2 期随机试验。
N Engl J Med. 2024 Jul 25;391(4):311-319. doi: 10.1056/NEJMoa2401755. Epub 2024 Jun 7.
6
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.司美格鲁肽用于肥胖治疗：SYNCHRONIZE心血管结局试验的理论依据与设计
JACC Heart Fail. 2024 Dec;12(12):2101-2109. doi: 10.1016/j.jchf.2024.09.004. Epub 2024 Oct 23.
7
The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.双重 GCGR/GLP-1R 激动剂 survodutide：用于临床候选药物选择的生物标志物和药理学特征分析。
Diabetes Obes Metab. 2024 Jun;26(6):2368-2378. doi: 10.1111/dom.15551. Epub 2024 Apr 1.
8
Perspectives in weight control in diabetes - Survodutide.糖尿病体重控制的前景——司美格鲁肽
Diabetes Res Clin Pract. 2024 Jan;207:110779. doi: 10.1016/j.diabres.2023.110779. Epub 2023 Jun 15.
9
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).司美格鲁肽治疗肥胖症：两项随机3期临床试验（SYNCHRONIZE™-1和-2）的原理与设计
Obesity (Silver Spring). 2025 Jan;33(1):67-77. doi: 10.1002/oby.24184. Epub 2024 Nov 4.
10
Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.胰高血糖素和GLP-1受体双重激动剂司美格鲁肽对体重减轻的影响：一项随机对照试验的荟萃分析
Diabetol Metab Syndr. 2024 Nov 6;16(1):264. doi: 10.1186/s13098-024-01501-x.

引用本文的文献

1
Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence.双重胰高血糖素和胰高血糖素样肽-1受体激动剂在心脏代谢连续体中的疗效：当前临床证据综述
Rev Cardiovasc Med. 2025 Jul 28;26(7):39691. doi: 10.31083/RCM39691. eCollection 2025 Jul.

本文引用的文献

1
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.MASH 和纤维化中苏沃杜肽的 2 期随机试验。
N Engl J Med. 2024 Jul 25;391(4):311-319. doi: 10.1056/NEJMoa2401755. Epub 2024 Jun 7.
2
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.胰高血糖素和 GLP-1 受体双重激动剂索马鲁肽治疗肥胖症的随机、双盲、安慰剂对照、剂量探索 2 期临床试验。
Lancet Diabetes Endocrinol. 2024 Mar;12(3):162-173. doi: 10.1016/S2213-8587(23)00356-X. Epub 2024 Feb 5.
3
Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults With Body Mass Index ≥27 kg/m: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy.
替尔泊肽可降低体重指数≥27kg/m²的成年人的24小时动态血压：SURMOUNT-1动态血压监测亚研究。
Hypertension. 2024 Apr;81(4):e41-e43. doi: 10.1161/HYPERTENSIONAHA.123.22022. Epub 2024 Feb 5.
4
Effect of tirzepatide on blood pressure levels in overweight/obese individuals without diabetes.替尔泊肽对无糖尿病超重/肥胖个体血压水平的影响。
Eur J Intern Med. 2024 Mar;121:155-156. doi: 10.1016/j.ejim.2023.12.022. Epub 2023 Dec 26.
5
The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis.司美格鲁肽对非糖尿病患者血压的影响：一项系统评价和荟萃分析
J Clin Med. 2023 Jan 18;12(3):772. doi: 10.3390/jcm12030772.
6
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.BI 456906：一种新型 GCGR/GLP-1R 双重激动剂的发现和临床前药理学研究，具有强大的抗肥胖疗效。
Mol Metab. 2022 Dec;66:101633. doi: 10.1016/j.molmet.2022.101633. Epub 2022 Nov 7.
7
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association.肥胖与心血管疾病：美国心脏协会科学声明
Circulation. 2021 May 25;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973. Epub 2021 Apr 22.
8
Effects of self-guided e-counseling on health behaviors and blood pressure: Results of a randomized trial.自我引导式电子咨询对健康行为和血压的影响：一项随机试验的结果。
Patient Educ Couns. 2020 Mar;103(3):635-641. doi: 10.1016/j.pec.2019.10.007. Epub 2019 Oct 19.
9
Role of Nutrition and Exercise Programs in Reducing Blood Pressure: A Systematic Review.营养与运动计划在降低血压中的作用：一项系统评价
J Clin Med. 2019 Sep 5;8(9):1393. doi: 10.3390/jcm8091393.
10
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.全国高血压防治联合委员会第七次报告：预防、检测、评估及治疗
Hypertension. 2003 Dec;42(6):1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2. Epub 2003 Dec 1.